title: Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1.
abstract: Infection with verotoxin-producing Escherichia coli has been implicated in the cause of hemolytic-uremic syndrome. Cases of thrombotic thrombocytopenic purpura and verotoxin infections have been also described. In this study we sought to determine the following: (1) whether verotoxin induces microvascular lesions in the rabbit, (2) the organ distribution of such lesions, and (3) the distribution of verotoxin glycolipid receptors in the various organs. Rabbits challenged with verotoxin-1 purified from E. coli O157:H7 had anorexia, lethargia, and limb paralysis; renal function, however, was normal. Central nervous system lesions found included pericellular and perivascular edema, focal hemorrhage, vascular lesions, and severe alterations of Purkinje cells. Histologic changes were also seen in the colon, with mucosal and submucosal edema and hemorrhage, and in the lung, with interstitial fibrosis and focal lymphohistiocitic infiltration. No lesions were detected in kidney, heart, liver, and spleen. Screening of various tissues for the presence of the verotoxin receptors revealed galabiosyl ceramide in the central nervous system and globotriosyl ceramide in the gastrointestinal tract, lung, and spleen. No receptors for verotoxin were found in the heart, liver, and kidney. These results indicate that organ localization of the disease in rabbits is dependent on the distribution of verotoxin receptors.
authors.affiliation: Mario Negri Institute for Pharmacological Research, Division of Nephrology, Ospedali Riuniti, Bergamo, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Zoja
authors.forename: D
authors.initials: D
authors.lastname: Corna
authors.forename: C
authors.initials: C
authors.lastname: Farina
authors.forename: G
authors.initials: G
authors.lastname: Sacchi
authors.forename: C
authors.initials: C
authors.lastname: Lingwood
authors.forename: M P
authors.initials: MP
authors.lastname: Doyle
authors.forename: V V
authors.initials: VV
authors.lastname: Padhye
authors.forename: M
authors.initials: M
authors.lastname: Abbate
authors.forename: G
authors.initials: G
authors.lastname: Remuzzi
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001427:Bacterial Toxins / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D001921:Brain / Q000187:drug effects / Q000473:pathology*; D002531:Cerebellum / Q000187:drug effects / Q000473:pathology; D003106:Colon / Q000187:drug effects / Q000473:pathology*; D004487:Edema / Q000139:chemically induced / Q000473:pathology; D004768:Enterotoxins / Q000633:toxicity*; D004926:Escherichia coli; D006017:Glycolipids / Q000032:analysis / Q000378:metabolism*; D007275:Injections, Intravenous; D008297:Male; D011817:Rabbits; D011956:Receptors, Cell Surface / Q000032:analysis / Q000378:metabolism*; D012016:Reference Values; D022622:Shiga Toxin 1; D013116:Spinal Cord / Q000187:drug effects / Q000473:pathology*
chemical_list: D001427:Bacterial Toxins; D004768:Enterotoxins; D006017:Glycolipids; D011956:Receptors, Cell Surface; D022622:Shiga Toxin 1; C068556:Shiga-like toxin receptor